BackCD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AMLMarch 21, 2025Read MoreA Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-EngagementJanuary 10, 2025Read MoreBasic Cancer Immunology for CliniciansDecember 26, 2024Read MoreUniversal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapyNovember 27, 2024Read MoreChimeric antigen receptor T cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity in vivoNovember 7, 2024Read MoreCAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastomaOctober 23, 2024Read MoreGD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasOctober 23, 2024Read MoreRevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastomaOctober 2, 2024Read MoreFOXO1 enhances CAR T cell stemness, metabolic fitness and efficacyJuly 3, 2024Read MoreEffective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression…June 14, 2024Read MoreResearch Highlights and TTCI Internal Meeting Part IIIJune 6, 2024Read MorePreclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complexJune 5, 2024Read MoreOlder PostsNewer Posts
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AMLMarch 21, 2025Read More
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-EngagementJanuary 10, 2025Read More
Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapyNovember 27, 2024Read More
Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity in vivoNovember 7, 2024Read More
CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastomaOctober 23, 2024Read More
RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastomaOctober 2, 2024Read More
Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression…June 14, 2024Read More
Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complexJune 5, 2024Read More
